Related Experiment Videos
[Antisense oligodeoxynucleotides of human telomerase reverse transcriptase inhibit endometrial carcinoma cell HEC-1A
Xue-jun Chen1, Wei Zheng, Sheng-qi Wang
1Medical College of Zhejiang University, HangZhou 310006, China.
Objective:
To evaluate antisense technology for human telomerase inhibition in the treatment of endometrial cancer.
Methods:
An antisense oligodeoxynucleotides (AODN) directed against the human telomerase transcriptase (hTERT), designed and synthesized to serve as a telomerase inhibitor, was transfected into endometrial carcinoma cell line HEC-1A by lipofectin. Reverse transcription-polymerase chain reaction (RT-PCR) and Western blot were used to test the expression of hTERT mRNA and hTERT protein before and after transfection. Telomerase activity was tested by telomeric repeat amplification protocol. The proliferation and growth of HEC-1A were also studied by methyl thiazolyl tetrazolium and cell growth curve before and after transfection.
Results:
AODN could down-regulate the expression of hTERT mRNA and protein, inhibiting telomerase activity and proliferation of endometrial cancer cell line in a dose- and period-dependent manner.
Conclusion:
Antisense oligodeoxynucleotides of human telomerase transcriptase definitely inhibits the proliferation of endometrial cancer cell line. Telomerase inhibitor may thus become a new gene therapeutic agent for endometrial carcinoma.
Insights
Antisense technology effectively inhibits endometrial cancer cell proliferation by targeting human telomerase transcriptase (hTERT). This novel approach shows promise as a gene therapeutic agent for endometrial carcinoma.
Area of Science:
- Molecular Biology
- Cancer Research
- Gene Therapy
Context:
- Endometrial cancer is a significant gynecologic malignancy.
- Telomerase plays a crucial role in cancer cell immortalization and proliferation.
- Targeting telomerase presents a potential therapeutic strategy for endometrial carcinoma.
Purpose:
- To evaluate the efficacy of antisense technology in inhibiting human telomerase.
- To assess the impact of antisense oligodeoxynucleotides (AODN) targeting hTERT on endometrial cancer cell line HEC-1A.
- To determine the potential of telomerase inhibition as a gene therapeutic approach for endometrial carcinoma.
Summary:
- Antisense oligodeoxynucleotides (AODN) targeting human telomerase transcriptase (hTERT) were synthesized and transfected into the HEC-1A endometrial cancer cell line.
- RT-PCR and Western blot confirmed down-regulation of hTERT mRNA and protein expression.
- Telomerase activity, cell proliferation, and growth were significantly inhibited in a dose- and time-dependent manner.
Impact:
- Antisense technology targeting hTERT demonstrates potent inhibition of endometrial cancer cell proliferation.
- This study supports the development of telomerase inhibitors as novel gene therapeutic agents for endometrial carcinoma.
- Findings contribute to the advancement of targeted cancer therapies.